A nonmitogenic pituitary function of fibroblast growth factor: Regulation of thyrotropin and prolactin secretion (releasing Contributed by Roger Guillemin, April 24, 1985 ABSTRACT
The widespread distribution of fibroblast growth factor (FGF) in several tissues as diverse as pituitary, brain, adrenal, ovary, kidney, macrophage, retina, and chondrosarcoma (1-6,*) was recently established with the availability of sequence-specific antisera (7) and the amino acid sequence information obtained from its structural characterization (2) . These observations suggested that the pituitary was not the source of FGF for other tissues (6) and that the diverse target-cell population stimulated by FGF in vitro (8) is correlated with paracrine, if not autocrine, activities in vivo. Thus, the capacity of FGF to induce angiogenesis, induce neovascularization, and promote injury repair (9-11) may reflect its local presence in tumors, placenta, and macrophage, respectively. Similarly, its mitogenic effect on normal adrenal and granulosa cells may reflect an in situ, local function that would explain its presence in adrenal, corpus luteum, and ovary. It was with this possibility in mind that we tested the hypothesis that the physiological function of the FGF detected, isolated, and characterized from the pituitary is in the regulation of pituitary hormone secretion.
MATERIALS AND METHODS Preparation of Pituitary Cell Cultures. Rat anterior pituitaries were collected from male Sprague-Dawley rats (125 g) and processed for cell culture by collagenase digestion (7, 12) . Cells were seeded at a density of 0.5-1 x 105 cells per ml into miniwell plates and incubated at 37°C in a humiditycontrolled atmosphere containing 8% CO2. On day 5 of culture, the cells were washed with Dulbecco's modified Eagle's medium (DMEM) and incubated with 900 ,ul of fresh DMEM supplemented with 0.1% bovine serum albumin. Releasing factors, in the presence or absence of FGF, were added to the cells in a 100-,ul aliquot for a period of 4 hr. In each instance, as described elsewhere (12) , the response to each releasing factor was the same whether they were added to the cells individually or together. The medium was collected and diluted, and the appropriate aliquots were used for the measurement of growth hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), corticotropin (ACTH), thyrotropin (TSH), and prolactin (PRL).
Radioimmunoassays. LH, FSH, TSH, PRL, and GH concentrations were all measured with reagents provided by the National Pituitary Agency of the National Institutes of Health, except for GH, in which case an antibody raised against mouse GH was used (13) . ACTH was measured by using an antibody (Acl) raised against ACTH1l24 (14) . Proteins and peptides were radioiodinated by the method of Greenwood et al. (15) .
Peptide and Protein Preparation. Synthetic rat ACTH1_39, rat ACTH (corticotropin)-releasing factor (CRF), rat GHreleasing factor (GRF), LH-releasing factor (LRF), and TSH-releasing factor (TRF) were prepared in this laboratory by solid-phase synthesis (16, 17) . The FGF used in these studies was prepared from bovine pituitaries by the method described by Gospodarowicz et al. (3) . Homogeneity of the mitogen was established in this laboratory by NaDodSO4/gel electrophoresis, amino acid analysis, reverse-phase HPLC, and amino-terminal sequencing. Quality control data is available on request.
Cell Number Determination. The primary cultures of rat pituitary cells were treated with 1 ml of trypsin-EDTA containing 0.9% NaCl, 0.01 M sodium phosphate, 0.05% trypsin, and 0.02% EDTA. The cells were triturated to obtain a single-cell suspension, and cell number was determined with a Coulter Counter.
Statistical Analysis. The dose-response curves were calculated according to the best-fit program (Allfit) described by De Lean et al. (18) . Potencies were determined by the "Bioprog" method described by Rodbard (19) 1A ). As expected, FGF also had no effect on cell number during the 4-hr incubation period (not shown). When the cells were preincubated with FGF for 48 hr prior to addition of releasing factors (Fig. 1B) , there was a significant increase in the amounts of PRL (P < 0.01) and TSH (P < 0.01) released from the TRF-stimulated cells. None of the other pituitary hormones was affected by the addition of FGF. Although basal PRL release was increased (P < 0.05), there was no effect on the basal release of TSH. The number of cells in the wells treated with FGF increased from 1.88 ± 0.05 x 105 to 2.04 ± 0.05 x 105 cells per well (P < 0.05).
Effect of FGF on the Dose-Response to TRF. The dose-response to TRF on the release of PRL and TSH is significantly modified by FGF (Fig. 2) . In this instance, cells were treated for two periods of 24 hr with 2 ng of FGF, followed by an acute (4 hr) incubation with various concentrations of TRF. Potency analysis of the dose-response curves (18, 19) (Fig. 3) . Basal TSH release was unaffected by the preincubation with any of the doses of FGF tested (Fig. 3 Middle). Basal PRL was significantly increased by treatment with the 2-ng dose of FGF (P < 0.01) (Fig. 3 Top) . The TSH and PRL response to TRF was modified by FGF at 0.2 and 2 ng/ml (P < 0.01) (Fig.  3 Middle). PRL release was also changed by the pretreatment with FGF at 0.02 ng/ml (P < 0.05) (Fig. 3 Top). Cell growth was also modified by FGF (Fig. 3 Bottom) as a function of the concentration of mitogen.
The effect of FGF is time-dependent, with a minimum of 24 hr of treatment required to observe the modified pituitary response (Fig. 4) . There was no effect of FGF on basal TSH release at any of the times of preincubation (Fig. 4 Middle). Basal PRL release was increased with the 48-and 72-hr treatments (P < 0.05), and both stimulated PRL (P < 0.05) and TSH (P < 0.01) releases were significantly increased after a 24-hr treatment with FGF ( Fig. 4 Top and Middle). The growth of cells was also time-dependent (Fig. 4 Bottom) . FGF increased basal cell growth as early as 24 hr after the initiation of the experiment (P < 0.05). Effect of the Inhibition of Cel Growth. Because FGF is a potent mitogen for several cell types, including the mixed population of pituitary cells used here as well as other endocrine cells (9,*), we investigated the possibility that FGF acts by stimulating the proliferation of lactotrophs and thyrotrophs. The approach used was to prevent basal and FGF-stimulated cell growth with 5-fluorodeoxyuridine (5-FdU) (Fig. 5 ). The treatment with 5-FdU effectively inhibited the growth of control cells and completely blocked the effect of FGF on cell number (P < 0.01) (Fig. 5 Bottom). The density of cells prior to the 48-hr treatment with 5-FdU (0.62 x 105 cells per well) remained the same throughout the incubation time. There was no evidence to suggest cell death as determined by trypan blue exclusion. At the same time, 5- FdU had no effect of basal TSH release (Fig. 5 Middle), and pretreatment of either control or 5-FdU-treated cells with FGF still gave an increased TSH response to TRF (10 nM; P < 0.01). Consistent with the demonstration by Pasteels (20) that lactotrophs do grow in culture, the treatment ofcells with 5-FdU decreased significantly (P < 0.01) basal PRL release was determined after trypsinization by using a Coulter particle counter. Each point is the mean of six replicate wells. *, P < 0.05; **, P < 0.01. (Fig. 5 Top) . In spite of this inhibition, FGF (2 ng/ml) remained effective in increasing both basal and TRF-stimulated PRL release by the 5-FdU-treated cells (P < 0.01). Therefore, after a 48-hr treatment with FGF, the magnitude ofthe response to TRF is the same with or without the growth inhibitor, even though throughout this period there was no cell growth. The purity of the growth factor used and the potency (10 pM) of its pituitary effects preclude the possibility that the activity reported here is not an intrinsic activity of FGF itself. Therefore On day 3 of culture, 2 ng of FGF was added to six wells (labeled 72 hr). The following day, this exact treatment was repeated to these same cells along with a second set of six wells (labeled 48 hr). Twenty-four hours later, FGF was added again to these cells as well as to a third set of dishes (labeled 24 hr). The following day, cells that had either not seen any FGF (o) or cells that had been preincubated for 1 day (24 hr), 2 days (48 hr), or 3 days (72 hr) with FGF were washed and incubated with medium alone (e) or with medium containing 10 nM TRF (0). At the end of the experiment, cell number (Bottom) was determined after trypsinization by using a Coulter particle counter. Each point is the mean of six determinations.
pituitary hormone at all effective doses. It would also explain the effect of FGF on basal PRL release; the removal of the normal dopaminergic inhibition of PRL (21) The observations reported here raise totally new questions pertaining to the physiological role of FGF in various tissues. They offer the possibility that the in situ function of FGF may not necessarily be exclusively linked to the stimulation of cell growth. This is of particular importance since FGF is widely distributed with apparent ubiquity in several tissues of distinct functional, embryological, and neurophysiological origin. Moreover, it can be detected in considerable quantities (1-6,*). On the basis of the results presented here, we propose that pituitary FGF participates in an intrapituitary mechanism regulating normal PRL/TSH secretion and actually may be involved in the pathophysiological expression of these hormones. The discovery that a potent growth factor like FGF, classically considered in events such as wound healing, tissue repair, and angiogenesis (9-11), can modulate cell function independently of its effects as a growth factor per se opens another dimension in the understanding of the normal physiology and pathophysiology of growth factors. Its local presence in the adrenal, ovary, corpus luteum, liver, and kidney (6,*) may well reflect, as in the pituitary, an intraglandular regulation of function as well as growth. Its presence in tissues such as macrophages (4) suggests that, as a paracrine activity, it may be involved in wound healing and, possibly, in pathophysiological states and atherosclerosis. In this model, the in situ physiological role of FGF in any given tissue would be a direct function of the local cellular milieu in which it is released. Moreover, the respective mechanisms of regulating growth and function need not be mutually exclusive.
